Comparing efficacy of first-line atypical antipsychotics: no evidence of differential efficacy between risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole
Authors:
- 1 January 2005
- journal article
- research article
- Published by Taylor & Francis in International Journal of Psychiatry in Clinical Practice
- Vol. 9 (3) , 204-212
Abstract
To evaluate the comparative efficacy of the first-line atypical antipsychotics risperidone, olanzapine, quetiapine, ziprasidone, and aripiprazole. Methods We reviewed published short-term, randomised, controlled clinical trials of first-line atypical antipsychotics in the treatment of schizophrenia or schizoaffective disorder that used the Positive and Negative Syndrome Scale to assess efficacy. We used a combined overview analysis to compare the extent of improvement in global symptoms and positive and negative symptoms. We did not analyse adverse event data. Results Although we found considerable variation in the degree of improvement with a particular atypical antipsychotic across different studies, the range and average improvement were similar among all first-line atypicals for all efficacy parameters considered. Dosage was a critical determinant of efficacy, although the most effective dose of each agent varied across studies. There were insufficient data for ziprasidone and aripiprazole to allow their inclusion in the formal overview comparison. Conclusion Despite confounding and methodological limitations, the data we reviewed do not support assertions of differential efficacy between the first-line atypical antipsychotics. Additional controlled comparative studies of the atypical antipsychotics should be of particular interest.Keywords
This publication has 51 references indexed in Scilit:
- Neurocognitive Effects of Clozapine, Olanzapine, Risperidone, and Haloperidol in Patients With Chronic Schizophrenia or Schizoaffective DisorderAmerican Journal of Psychiatry, 2002
- A Randomized Double-Blind Study of Risperidone and Olanzapine in the Treatment of Schizophrenia or Schizoaffective DisorderAmerican Journal of Psychiatry, 2001
- Studies of Cognitive Change in Patients With Schizophrenia Following Novel Antipsychotic TreatmentAmerican Journal of Psychiatry, 2001
- A multicentre, double-blind, randomized comparison of quetiapine (ICI 204,636, ‘Seroquel’) and haloperidol in schizophreniaPsychological Medicine, 2000
- Ziprasidone 80 mg/day and 160 mg/day in the Acute Exacerbation of Schizophrenia and Schizoaffective Disorder A 6-Week Placebo-Controlled TrialNeuropsychopharmacology, 1999
- Therapeutic Equivalence of Risperidone Given Once Daily and Twice Daily in Patients With SchizophreniaJournal of Clinical Psychopharmacology, 1998
- Antipsychotic and Anxiolytic Properties of Risperidone, Haloperidol, and Methotrimeprazine in Schizophrenic PatientsJournal of Clinical Psychopharmacology, 1996
- Risperidone in the Treatment of Patients with Chronic Schizophrenia: a Multi-National, Multi-Centre, Double-Blind, Parallel-Group Study versus HaloperidolThe British Journal of Psychiatry, 1995
- Can meta-analyses be trusted?The Lancet, 1991
- Bias in Treatment Assignment in Controlled Clinical TrialsNew England Journal of Medicine, 1983